A Phase 2 interventional study of ETC-1002 and Placebo in Hypercholesterolemia and Hypertension, sponsored by Esperion Therapeutics, Inc.. Completed at 43 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-04-04.
Sponsored by Esperion Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing bempedoic acid in Hypercholesterolemia — 1 open to participants now, 1 under way, 1 of them phase 3. bempedoic acid · Hypercholesterolemia.
Among the 21 studies testing bempedoic acid in Hypercholesterolemia, this one is the 9th largest by enrollment, is one of 2 that started in 2014, is one of 10 in phase 2, and was the 5th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →1 of the 21 studies testing bempedoic acid in Hypercholesterolemia is open now, in 3 countries. Recruiting first, the newest first:
Daiichi Sankyo · Sites in Germany, Italy, Spain
Ages 18+
By country, each count listing its studies:
bempedoic acid: first FDA approval 2020 (NEXLETOL), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 143 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 126 across the 21 interventional studies. Of the 20 that completed or were terminated, 12 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 21 have an industry lead sponsor. The 6 most frequent:
Esperion Therapeutics, Inc. is the lead sponsor of 24 studies on the registry; 1 is open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
15 studies in Hypercholesterolemia by Esperion Therapeutics, Inc.: none open now, none under way, none of them phase 3. Of 15 finished, 11 (73%) have results posted.
Among the 15 studies in Hypercholesterolemia by Esperion Therapeutics, Inc., this one is the 8th largest by enrollment, is one of 2 that started in 2014, is one of 9 in phase 2, and was the 5th registered.
Esperion Therapeutics, Inc.’s Hypercholesterolemia studies by the year they started, since 2012.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing bempedoic acid in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Esperion Therapeutics, Inc.’s 15 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This Phase 2 study will assess the efficacy and safety of ETC-1002 monotherapy versus placebo in participants with hypercholesterolemia and hypertension.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ETC-1002 180 mg/day
Drug: ETC-1002
Placebo control
Drug: Placebo
ETC-1002 capsules taken once daily
Placebo capsules taken once daily
Percent Change From Baseline in Calculated Low-density Lipoprotein Cholesterol (LDL-C) to Week 6
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Week -1 and Week 0. Percent change from Baseline in LDL-C was analyzed using an analysis of covariance (ANCOVA) model with a term for treatment and Baseline value as a covariate. The Week 6 endpoint was the last available post-Baseline value. For the Week 6 endpoint, missing values at Week 6 were imputed using the last observation carried forward (LOCF) procedure, with only post-Baseline values carried forward. Modified Intent-to-Treat (mITT) Population is defined as all randomized participants who received at least 1 dose of study drug, had a Baseline assessment, and had at least 1 post-Baseline assessment, excluding any assessment taken more than 2 days after a dose of study drug
Time frame: Baseline; 6 weeks
Change From Baseline in Mean 24-hour Systolic Blood Pressure (SBP) to Week 6
Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the last value prior to the first dose of study medication. Change from Baseline was calculated using an ANCOVA model with a term for treatment and Baseline value as a covariate. The Week 6 endpoint was the last available post-Baseline value.
Time frame: Baseline; 6 weeks
Change From Baseline in 24-hour Mean Diastolic Blood Pressure (DBP) to Week 6
Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the last value prior to the first dose of study medication. Change from Baseline was calculated using an ANCOVA model with a term for treatment and Baseline value as a covariate. The Week 6 endpoint was the last available post-Baseline value.
Time frame: Baseline; 6 weeks
Change From Baseline in Mean Daytime SBP to Week 6
Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the last value prior to the first dose of study medication. Change from Baseline was calculated using an ANCOVA model with a term for treatment and Baseline value as a covariate. Daytime measurements were defined as those taken from 7 AM to 10 PM (\>7 AM and ≤10 PM). The Week 6 endpoint was the last available post-Baseline value.
Time frame: Baseline; 6 weeks
Change From Baseline in Mean Daytime DBP to Week 6
Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the last value prior to the first dose of study medication. Change from Baseline was calculated using an ANCOVA model with a term for treatment and Baseline value as a covariate. Daytime measurements were defined as those taken from 7 AM to 10 PM (\>7 AM and ≤10 PM). The Week 6 endpoint was the last available post-Baseline value.
Time frame: Baseline; 6 weeks
Change From Baseline in Mean Nighttime SBP to Week 6
Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the last value prior to the first dose of study medication. Change from Baseline was calculated using an ANCOVA model with a term for treatment and Baseline value as a covariate. Nighttime measurements were defined as those taken from 10 PM to 7 AM (\>10 PM and ≤7 AM). The Week 6 endpoint was the last available post-Baseline value.
Time frame: Baseline; 6 weeks
Change From Baseline in Mean Nighttime DBP to Week 6
Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the last value prior to the first dose of study medication. Change from Baseline was calculated using an ANCOVA model with a term for treatment and Baseline value as a covariate. Nighttime measurements were defined as those taken from 10 PM to 7 AM (\>10 PM and ≤7 AM). The Week 6 endpoint was the last available post-Baseline value.
Time frame: Baseline; 6 weeks
Change From Baseline in Sitting Cuff SBP to Week 6
Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the mean of the values from Weeks -1 and 0. Change from Baseline was calculated using an ANCOVA model with a term for treatment and Baseline value as a covariate. Three BP measurements were collected at least 3 minutes apart, and the mean of the second and third measurements was calculated and used for summary and analysis. The Week 6 endpoint was the last available post-Baseline value.
Time frame: Baseline: 6 weeks
Change From Baseline in Sitting Cuff DBP to Week 6
Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the mean of the values from Weeks -1 and 0. Change from Baseline was calculated using an ANCOVA model with a term for treatment and Baseline value as a covariate. Three BP measurements were collected at least 3 minutes apart, and the mean of the second and third measurements was calculated and used for summary and analysis. The Week 6 endpoint was the last available post-Baseline value.
Time frame: Baseline; 6 weeks
Percent Change From Baseline in High-sensitivity C-reactive Protein (hsCRP) to Week 6
A non-parametric analysis was performed for hsCRP parameters. Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the last value prior to the first dose of study medication. If hsCRP was \<0.2, 0.1 was imputed for analysis. The Week 6 endpoint was the last available post-Baseline value.
Time frame: Baseline; 6 weeks
Percent Change From Baseline in Total Cholesterol to Week 6
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Week -1 and Week 0. Change from Baseline was calculated using an ANCOVA model with terms for treatment and statin intolerance, and value as a covariate. The Week 6 endpoint was the last available post-Baseline value.
Time frame: Baseline; 6 weeks
Percent Change From Baseline in Apolipoprotein B (ApoB) to Week 6
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Week -1 and Week 0. Change from Baseline was calculated using an ANCOVA model with terms for treatment and statin intolerance, and Baseline value as a covariate. The Week 6 endpoint was the last available post-Baseline value.
Time frame: Baseline; 6 weeks
Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) to Week 6
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the last value prior to the first dose of study medication. Change from Baseline was calculated using an ANCOVA model with a term for treatment and Baseline value as a covariate. The Week 6 endpoint was the last available post-Baseline value.
Time frame: Baseline; 6 weeks
Percent Change From Baseline in Triglycerides (TG) to Week 6
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Week -1 and Week 0. The Week 6 endpoint was the last available post-Baseline value. Data was analyzed using non-parametric analysis.
Time frame: Baseline; 6 weeks
Percent Change From Baseline in HDL-C to Week 6
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Week -1 and Week 0. Change from Baseline was calculated using an ANCOVA model with terms for treatment and statin intolerance, and Baseline value as a covariate. The Week 6 endpoint was the last available post-Baseline value.
Time frame: Baseline; 6 weeks
Percent Change From Baseline in Free Fatty Acids (FFA) to Week 6
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Week -1 and Week 0. The Week 6 endpoint was the last available post-Baseline value.
Time frame: Baseline; 6 weeks
Change From Baseline in Body Weight to Week 6
Baseline was defined as the mean of the values from Week -1 and Week 0. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline; 6 weeks
Plasma Trough Concentrations of ETC-1002 and Metabolite ESP15228
Plasma trough concentration is defined as the lowest concentration reached before the next dose is administered.
Time frame: Week 2, Week 4 and Week 6
| Milestone | Placebo | ETC-1002 180 mg |
|---|---|---|
| Started | 72 | 71 |
| Completed | 67 | 59 |
| Not completed | 5 | 12 |
| Withdrew: Withdrawal by subject | 0 | 6 |
| Withdrew: Adverse event | 1 | 2 |
| Withdrew: Protocol violation | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Sponsor request | 1 | 0 |
| Withdrew: Other | 2 | 2 |
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Week -1 and Week 0. Percent change from Baseline in LDL-C was analyzed using an analysis of covariance (ANCOVA) model with a term for treatment and Baseline value as a covariate. The Week 6 endpoint was the last available post-Baseline value. For the Week 6 endpoint, missing values at Week 6 were imputed using the last observation carried forward (LOCF) procedure, with only post-Baseline values carried forward. Modified Intent-to-Treat (mITT) Population is defined as all randomized participants who received at least 1 dose of study drug, had a Baseline assessment, and had at least 1 post-Baseline assessment, excluding any assessment taken more than 2 days after a dose of study drug
| Percent Change | Placebo | ETC-1002 180 mg |
|---|---|---|
| Percent Change From Baseline in Calculated Low-density Lipoprotein Cholesterol (LDL-C) to Week 6 | 3.16 ± 2.133 | -21.08 ± 2.196 |
Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the last value prior to the first dose of study medication. Change from Baseline was calculated using an ANCOVA model with a term for treatment and Baseline value as a covariate. The Week 6 endpoint was the last available post-Baseline value.
| millimeters of mercury (mmHg) | Placebo | ETC-1002 180 mg |
|---|---|---|
| Change From Baseline in Mean 24-hour Systolic Blood Pressure (SBP) to Week 6 | -0.64 ± 1.045 | -2.28 ± 1.085 |
Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the last value prior to the first dose of study medication. Change from Baseline was calculated using an ANCOVA model with a term for treatment and Baseline value as a covariate. The Week 6 endpoint was the last available post-Baseline value.
| mmHg | Placebo | ETC-1002 180 mg |
|---|---|---|
| Change From Baseline in 24-hour Mean Diastolic Blood Pressure (DBP) to Week 6 | -0.05 ± 0.760 | -1.10 ± 0.790 |
Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the last value prior to the first dose of study medication. Change from Baseline was calculated using an ANCOVA model with a term for treatment and Baseline value as a covariate. Daytime measurements were defined as those taken from 7 AM to 10 PM (\>7 AM and ≤10 PM). The Week 6 endpoint was the last available post-Baseline value.
| mmHg | Placebo | ETC-1002 180 mg |
|---|---|---|
| Change From Baseline in Mean Daytime SBP to Week 6 | -0.35 ± 1.198 | -2.66 ± 1.245 |
Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the last value prior to the first dose of study medication. Change from Baseline was calculated using an ANCOVA model with a term for treatment and Baseline value as a covariate. Daytime measurements were defined as those taken from 7 AM to 10 PM (\>7 AM and ≤10 PM). The Week 6 endpoint was the last available post-Baseline value.
| mmHg | Placebo | ETC-1002 180 mg |
|---|---|---|
| Change From Baseline in Mean Daytime DBP to Week 6 | -0.01 ± 0.856 | -1.47 ± 0.890 |
Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the last value prior to the first dose of study medication. Change from Baseline was calculated using an ANCOVA model with a term for treatment and Baseline value as a covariate. Nighttime measurements were defined as those taken from 10 PM to 7 AM (\>10 PM and ≤7 AM). The Week 6 endpoint was the last available post-Baseline value.
| mmHg | Placebo | ETC-1002 180 mg |
|---|---|---|
| Change From Baseline in Mean Nighttime SBP to Week 6 | -1.18 ± 1.167 | -1.57 ± 1.212 |
Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the last value prior to the first dose of study medication. Change from Baseline was calculated using an ANCOVA model with a term for treatment and Baseline value as a covariate. Nighttime measurements were defined as those taken from 10 PM to 7 AM (\>10 PM and ≤7 AM). The Week 6 endpoint was the last available post-Baseline value.
| mmHg | Placebo | ETC-1002 180 mg |
|---|---|---|
| Change From Baseline in Mean Nighttime DBP to Week 6 | -0.52 ± 0.879 | -0.33 ± 0.913 |
Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the mean of the values from Weeks -1 and 0. Change from Baseline was calculated using an ANCOVA model with a term for treatment and Baseline value as a covariate. Three BP measurements were collected at least 3 minutes apart, and the mean of the second and third measurements was calculated and used for summary and analysis. The Week 6 endpoint was the last available post-Baseline value.
| mmHg | Placebo | ETC-1002 180 mg |
|---|---|---|
| Change From Baseline in Sitting Cuff SBP to Week 6 | -4.98 ± 1.274 | -3.45 ± 1.311 |
Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the mean of the values from Weeks -1 and 0. Change from Baseline was calculated using an ANCOVA model with a term for treatment and Baseline value as a covariate. Three BP measurements were collected at least 3 minutes apart, and the mean of the second and third measurements was calculated and used for summary and analysis. The Week 6 endpoint was the last available post-Baseline value.
| mmHg | Placebo | ETC-1002 180 mg |
|---|---|---|
| Change From Baseline in Sitting Cuff DBP to Week 6 | -3.32 ± 0.820 | -2.53 ± 0.844 |
A non-parametric analysis was performed for hsCRP parameters. Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the last value prior to the first dose of study medication. If hsCRP was \<0.2, 0.1 was imputed for analysis. The Week 6 endpoint was the last available post-Baseline value.
| Percent Change | Placebo | ETC-1002 180 mg |
|---|---|---|
| Percent Change From Baseline in High-sensitivity C-reactive Protein (hsCRP) to Week 6 | 19.61 (-16.67 to 64.29) | -25.00 (-50.85 to 0.00) |
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Week -1 and Week 0. Change from Baseline was calculated using an ANCOVA model with terms for treatment and statin intolerance, and value as a covariate. The Week 6 endpoint was the last available post-Baseline value.
| Percent Change | Placebo | ETC-1002 180 mg |
|---|---|---|
| Percent Change From Baseline in Total Cholesterol to Week 6 | 2.90 ± 1.389 | -13.77 ± 1.430 |
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Week -1 and Week 0. Change from Baseline was calculated using an ANCOVA model with terms for treatment and statin intolerance, and Baseline value as a covariate. The Week 6 endpoint was the last available post-Baseline value.
| Percent Change | Placebo | ETC-1002 180 mg |
|---|---|---|
| Percent Change From Baseline in Apolipoprotein B (ApoB) to Week 6 | 4.77 ± 1.797 | -14.13 ± 1.911 |
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the last value prior to the first dose of study medication. Change from Baseline was calculated using an ANCOVA model with a term for treatment and Baseline value as a covariate. The Week 6 endpoint was the last available post-Baseline value.
| Percent Change | Placebo | ETC-1002 180 mg |
|---|---|---|
| Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) to Week 6 | 3.20 ± 1.728 | -15.49 ± 1.779 |
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Week -1 and Week 0. The Week 6 endpoint was the last available post-Baseline value. Data was analyzed using non-parametric analysis.
| Percent Change | Placebo | ETC-1002 180 mg |
|---|---|---|
| Percent Change From Baseline in Triglycerides (TG) to Week 6 | -3.75 (-18.67 to 15.69) | -0.07 (-20.63 to 36.38) |
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Week -1 and Week 0. Change from Baseline was calculated using an ANCOVA model with terms for treatment and statin intolerance, and Baseline value as a covariate. The Week 6 endpoint was the last available post-Baseline value.
| Percent Change | Placebo | ETC-1002 180 mg |
|---|---|---|
| Percent Change From Baseline in HDL-C to Week 6 | 2.42 ± 1.614 | -5.76 ± 1.661 |
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Week -1 and Week 0. The Week 6 endpoint was the last available post-Baseline value.
| Percent Change | Placebo | ETC-1002 180 mg |
|---|---|---|
| Percent Change From Baseline in Free Fatty Acids (FFA) to Week 6 | 1.08 (-23.81 to 30.46) | 9.56 (-19.49 to 43.53) |
Baseline was defined as the mean of the values from Week -1 and Week 0. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| kilograms | Placebo | ETC-1002 180 mg |
|---|---|---|
| Change From Baseline in Body Weight to Week 6 | -0.335 ± 1.590 | -0.009 ± 1.927 |
Plasma trough concentration is defined as the lowest concentration reached before the next dose is administered.
| nanograms per milliliter (ng/mL) | ETC-1002 180 mg |
|---|---|
| Week 2, ETC-1002 | 6666.20 ± 4777.661 |
| Week 4, ETC-1002 | 6817.45 ± 4543.944 |
| Week 6, ETC-1002 | 6836.36 ± 3702.241 |
| Week 2, ESP15228 | 1219.60 ± 783.00 |
| Week 4, ESP15228 | 1220.79 ± 674.437 |
| Week 6, ESP15228 | 1221.32 ± 557.930 |
Collected over Up to approximately 14 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/72 (0%) | 2/72 (2.8%) | 4/72 (5.6%) |
| ETC-1002 180 mg | 0/71 (0%) | 4/71 (5.6%) | 3/71 (4.2%) |
| Event | Placebo | ETC-1002 180 mg |
|---|---|---|
| Non-cardiac chest painGeneral disorders | 0/72 | 2/71 |
| Atrial flutterCardiac disorders | 0/72 | 1/71 |
| Craniocerebral injuryInjury, poisoning and procedural complications | 0/72 | 1/71 |
| Acute myocardial infarctionCardiac disorders | 1/72 | 0/71 |
| Sinus tachycardiaCardiac disorders | 1/72 | 0/71 |
| Colon adenomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/72 | 0/71 |
| Event | Placebo | ETC-1002 180 mg |
|---|---|---|
| HeadacheNervous system disorders | 4/72 | 3/71 |
Baseline data are reported for members of the Safety Population, comprised of all randomized participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Placebo | ETC-1002 180 mg | Total |
|---|---|---|---|
| Mean | 56.5 ± 8.29 | 54.6 ± 8.41 | 55.6 ± 8.38 |
| Sex: Female, Male(Participants) | Placebo | ETC-1002 180 mg | Total |
|---|---|---|---|
| Female | 35 | 26 | 61 |
| Male | 37 | 45 | 82 |
| Race/Ethnicity, Customized(Participants) | Placebo | ETC-1002 180 mg | Total |
|---|---|---|---|
| Asian | 1 | 2 | 3 |
| Black or African American | 23 | 17 | 40 |
| White | 45 | 49 | 94 |
| More than one race | 1 | 2 | 3 |
| Unknown | 2 | 1 | 3 |
Ran from Jun 2014 to primary completion in May 2015, 11 months.
Results were first posted in Apr 2023, 7 years 10 months after primary completion. A results delay was requested in Aug 2015.
Of 41 industry-sponsored phase 2 interventional studies under Hypercholesterolemia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 14. This study's 11 months is above that.
Counting every sponsor, half of 48 studies reached it within 10 months; a quarter within 7 and three quarters within 18.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bempedoic acid